Welcome to our dedicated page for CASTLE BIOSCIENCES SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Castle Biosciences, Inc. filings document the regulatory record for a Delaware molecular diagnostics company with common stock listed on the Nasdaq Global Market under CSTL. Recent Form 8-K filings report quarterly and annual operating results, preliminary performance updates, and Regulation FD slide presentations tied to management communications.
The company’s proxy materials cover annual meeting matters, executive compensation, director elections, stockholder voting procedures, and governance disclosures. Other material-event filings document amendments to bylaws, including provisions related to stockholder meetings, director nominations, and board governance, alongside standing disclosures on registered securities and exchange listing status.
Castle Biosciences, Inc. (CSTL) is the issuer for a Form 144 notice filed on behalf of officer Derek Maetzold covering proposed sales of up to 29,014 shares of common stock through Goldman Sachs & Co. LLC. The filing states that these sales are made under a selling plan dated June 2, 2026 intended to comply with Rule 10b5-1(c).
The shares to be sold include 17,164 shares by Derek Maetzold, 5,445 shares by the Derek Maetzold 2020 Irrevocable Trust, and 6,405 shares by the Maetzold Descendants 2020 Trust, including shares acquired via compensation-related stock options and gifts. The filing also lists multiple common stock sales in the prior three months by Maetzold and related trusts.
CASTLE BIOSCIENCES INC (CSTL) reported that Chief Operating Officer Kristen M. Oelschlager exercised stock options for 4,152 shares of common stock at an exercise price of $3.38 per share on September 1, 2026, then sold 3,952 shares at a weighted-average price of $33.36 and an additional 200 shares at $34.02 in sale transactions made pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. She also reports indirect ownership of 72,649 shares held by the Fritz Shorter Trust, of which she and her spouse are trustees and beneficiaries.
CASTLE BIOSCIENCES INC (CSTL) reported that Chief Commercial Officer Juvenal W. Tobin sold 1,730 shares of common stock on August 31, 2026 in an open-market transaction at a weighted-average price of $32.81 per share, with individual trade prices ranging from $32.39 to $33.17.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025, and following this transaction Tobin directly holds 65,184 shares of Castle Biosciences common stock.
CASTLE BIOSCIENCES INC (CSTL) CEO and director Derek J. Maetzold reported an option exercise and related share sales. He exercised a stock option for 12,428 shares of Common Stock at an exercise price of $2.39 per share, from a fully vested option expiring May 9, 2028, leaving 25,329 option shares outstanding. On the same date, entities associated with him sold an aggregate of 18,560 shares of Common Stock, including direct holdings and shares held through several family and grantor retained annuity trusts, at weighted-average prices of approximately $33.14 and $33.88 per share. All transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025.
CASTLE BIOSCIENCES INC (CSTL) reported an insider transaction by Chief Commercial Officer Juvenal Tobin W. On August 25, 2026, he sold 9,050 shares of common stock in an open-market transaction at a weighted-average price of $35.04 per share, with individual trade prices ranging from $35.00 to $35.14. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. After this transaction, he held 66,914 shares of Castle Biosciences common stock directly.
CASTLE BIOSCIENCES INC (CSTL) reported that Chief Operating Officer Kristen M. Oelschlager had associated entities sell a total of 24,602 shares of common stock on August 24–25, 2026. The shares were sold indirectly through The Fritz Shorter Trust at weighted-average prices between approximately $33.50 and $34.75. Oelschlager also reports a direct holding of 13,288 shares of common stock after these transactions.
CASTLE BIOSCIENCES INC (CSTL) received a Rule 144 notice covering potential sales of its common stock by Chief Commercial Officer Tobin Juvenal. The notice lists 22,500 shares of common stock to be sold through Goldman Sachs & Co. LLC, with an indicated aggregate market value of $787,500, and notes that there were 30,549,507 shares outstanding as of the relevant date.
The shares relate to equity compensation awards, including restricted stock units and restricted stock awards granted between 2022 and 2025. The filing discloses that sales are being made under a selling plan dated December 10, 2025 that is intended to comply with Rule 10b5-1(c), with recent sales reported over the past three months.
CASTLE BIOSCIENCES INC (CSTL) received a Rule 144 notice indicating a proposed sale of common stock for the account of officer Kristen M. Oelschlager, with J.P. Morgan Securities LLC acting as agent and attorney-in-fact. The filing covers a proposed sale of 24,602 shares of common stock, with an indicated aggregate market value of $841,388.40. The notice states that the shares are held by The Fritz Shorter Trust, with Kristen and Michael Oelschlager as trustees, and were associated with an account retitled into the trust name on March 19, 2025. The issuer reports 30,549,507 shares of common stock outstanding as of the filing context.
CASTLE BIOSCIENCES INC (CSTL) reported that Chief Commercial Officer Juvenal Tobin W sold 1,730 shares of common stock on August 17, 2026 in an open-market or private transaction at a weighted-average price of $29.59 per share, under a Rule 10b5-1 trading plan adopted on December 10, 2025. The trades occurred in multiple lots between $29.21 and $30.01 per share, and Tobin now directly holds 75,964 shares of CSTL common stock.
CASTLE BIOSCIENCES INC (CSTL) reported that its Chief Financial Officer, Frank Stokes, sold common stock in an open-market transaction. On 2026-08-14, he sold 24,908 shares at a weighted-average price of $29.77 per share, executed in multiple trades between $29.71 and $29.97. Following this sale, he directly holds 35,177 shares of Castle Biosciences common stock.